Insider Trading July 24, 2026 07:16 AM

Kaltura Officer Eynav Azaria Executes $8,971 Stock Sale Under Pre-Arranged Plan

Insider transaction occurs as Kaltura reports Q1 2026 revenue exceeding forecasts, yet stock remains under pressure amid valuation concerns.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
KLTR

Kaltura Inc. (NASDAQ: KLTR) officer Eynav Azaria sold 6,301 shares of the company's common stock on July 22, 2026, generating $8,971 in proceeds. The transaction, executed at a weighted average price of $1.4239 per share, was conducted under a Rule 10b5-1 trading plan established in December 2025. This sale reduces Azaria's direct beneficial ownership to 2,156,522 shares. The transaction takes place against a backdrop of Kaltura's stock declining 29% over the past year, currently trading at $1.37, with a market capitalization of $206 million. Despite recent Q1 2026 earnings beating revenue expectations, the stock has faced downward pressure, reflecting mixed market signals regarding the company's financial performance and strategic investments.

Kaltura Officer Eynav Azaria Executes $8,971 Stock Sale Under Pre-Arranged Plan
KLTR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kaltura officer Eynav Azaria sold 6,301 shares for $8,971 under a Rule 10b5-1 plan adopted in December 2025.
  • Q1 2026 revenue of $44.6 million exceeded forecasts, yet the stock declined in aftermarket trading.
  • Kaltura's stock has declined 29% over the past year, currently trading at $1.37 with a $206 million market cap.

Insider trading activity at Kaltura Inc. (NASDAQ: KLTR) has drawn attention as officer Eynav Azaria executed a sale of company stock on July 22, 2026. Azaria divested 6,301 shares of common stock, resulting in a total transaction value of $8,971. The shares were sold at a weighted average price of $1.4239 per share, with individual transaction prices ranging between $1.41 and $1.44.

The sale was facilitated through a Rule 10b5-1 trading plan, a mechanism designed to allow insiders to trade stock in a manner that avoids allegations of insider trading. Azaria originally adopted this pre-arranged plan on December 15, 2025. Following the execution of this transaction, Azaria's direct beneficial ownership of Kaltura common stock stands at 2,156,522 shares.

This insider activity occurs within a challenging market context for Kaltura. The company's stock has experienced a significant decline of 29% over the past year. As of the reporting period, the stock is trading at $1.37, reflecting a market capitalization of $206 million. According to InvestingPro analysis, the stock currently appears overvalued relative to its calculated Fair Value.

Despite the stock's recent performance, the company's balance sheet shows strength, with more cash than debt. Analysts predict the company will achieve profitability this year. These insights are part of broader analysis available to subscribers, including a comprehensive Pro Research Report covering Kaltura and over 1,400 other US equities.

Financial performance data from Q1 2026 provides additional context to the current valuation environment. Kaltura reported revenue of $44.6 million, exceeding the forecast of $44.39 million. Earnings per share (EPS) aligned with projections at $0.01. Despite revenue surpassing estimates, the stock experienced a decline in aftermarket trading. This reflects a cautious market response amid mixed signals from the company's financial performance and strategic investments.

Investors evaluating Kaltura must consider these recent developments when assessing the company's outlook. The disparity between revenue beats and stock price performance highlights the complex dynamics affecting the company's valuation.

Risks

  • The stock appears overvalued relative to its Fair Value according to InvestingPro analysis.
  • Despite revenue beats, the stock has declined in aftermarket trading, indicating cautious market sentiment.
  • The company faces valuation pressures despite holding more cash than debt and predicted profitability.

More from Insider Trading

Rani Therapeutics Director Mir A Imran Acquires $24,839 in Stock Amid Clinical and Corporate Developments Jul 24, 2026 Cytokinetics EVP Fady Malik Sells Stock Amid Myqorzo Launch Momentum Jul 24, 2026 Acrivon Therapeutics CLO Mary Miller Sells $1,008 in Company Stock Jul 24, 2026 Rhinebeck Bancorp Director Loughlin Acquires $149,120 in Stock Amid Structural Transition Jul 24, 2026 Travelers Executive Michael Klein Executes $2.2 Million Stock Disposition Amid Mixed Analyst Sentiment Jul 24, 2026